Novartis AG
NVSEF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.72 | 0.11 | -0.39 | 0.04 |
| FCF Yield | 7.12% | 5.58% | 6.09% | 6.51% |
| EV / EBITDA | 10.32 | 11.41 | 13.83 | 11.92 |
| Quality | ||||
| ROIC | 15.55% | 11.49% | 8.05% | 9.89% |
| Gross Margin | 75.20% | 74.24% | 70.12% | 69.99% |
| Cash Conversion Ratio | 1.48 | 1.58 | 2.05 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.07% | -4.08% | 1.27% | 2.80% |
| Free Cash Flow Growth | 17.94% | 1.21% | -4.42% | 9.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.96 | 0.66 | 1.34 | 1.09 |
| Interest Coverage | 14.46 | 11.43 | 10.69 | 12.89 |
| Efficiency | ||||
| Inventory Turnover | 2.25 | 2.03 | 2.16 | 2.38 |
| Cash Conversion Cycle | 99.72 | 93.50 | 110.79 | 86.46 |